Delcath launches Hepzato Kit in US for uveal melanoma

IvelinRadkov/iStock via Getty Images Delcath Systems ( NASDAQ: DCTH ) said that it has launched its product Hepzato Kit in the US for the treatment of metastatic uveal melanoma. The company also announced the first commercial use of the product, which was conducted at the Moffitt Cancer Center in Tampa, Florida.

It added that it is working with other cancer centers around the country to ensure nationwide access. More on Delcath Systems Adoption Of Delcath's Hepzato Kit Will Snowball Quicker Than The Market Expects Delcath Systems Inc. (DCTH) Q3 2023 Earnings Call Transcript Delcath Systems Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Delcath Systems Historical earnings data for Delcath Systems.